Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Behavioural patterns in allergic rhinitis medication in Europe : a study using 28 MASK-air® real-world data
Authors:ID Sousa-Pinto, Bernardo (Author)
ID Sá-Sousa, Ana (Author)
ID Vieira, Rafael José (Author)
ID Amaral, Rita (Author)
ID Klimek, Ludger (Author)
ID Czarlewski, Wienczyslawa (Author)
ID Antò i Boquè, Josep M. (Author)
ID Pfaar, Oliver (Author)
ID Bedbrook, Anna (Author)
ID Zidarn, Mihaela, Klinika Golnik, Medicinska fakulteta UL (Author)
ID Fonseca, Joao A. (Author)
ID Bousquet, Jean (Author)
Files:URL URL - Source URL, visit
Typology:1.01 - Original Scientific Article
Organization:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Background. Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data. Methods. We analysed 2015-2020 MASK-air® European data. We compared days under no medication, monotherapy, and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms (“VAS Global Symptoms”) and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within one year. Results. We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy, and 38,315 (17.3%) under co-medication. The median “VAS Global Symptoms” was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p<0.001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H1-antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more. Conclusions. AR medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR), and that co-medication use is driven by symptom severity.
Keywords:asthma -- drug therapy, rhinitis -- drug therapy, allergic rhinitis -- drug therapy, visual analogue scale, histamine antagonists, antihistamines, behavioural patterns, medication patterns, real-world data
Publication status in journal:In print
Article version:Postprint, final article version, accepted into publication
Place of publishing:Velika Britanija
Publisher:John Wiley & Sons
Year of publishing:2022
Number of pages:str. 2699-2711
Numbering:Vol. 77, iss. 9
PID:20.500.12556/DiRROS-14823 New window
ISSN on article:1398-9995
DOI:10.1111/all.15275 New window
COBISS.SI-ID:100821507 New window
Note:Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Mihaela Zidarn; Opis vira z dne 14. 3. 2022;
Publication date in DiRROS:14.03.2022
Copy citation
Share:Bookmark and Share

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

COBISS.SI-ID:515009305 New window

Secondary language

Keywords:astma -- terapija z zdravili, rinitis -- terapija z zdravili, alergijski rinitis -- terapija z zdravili, vizualna analogna lestvica, histaminski antagonisti, antihistaminiki, vedenjski vzorci, vzorci zdravljenja, podatki iz resničnega življenja